Definium Therapeutics, Inc. (DFTX) /
The debt of Definium Therapeutics, Inc. over the past 6 years
Chart Definium Therapeutics, Inc.: liquid cash, total debt, net cash, fiscal 2020–2025 Open the chart →At the end of fiscal 2025, the latest fiscal year on file, Definium Therapeutics, Inc. had liquid cash of $411.59M and total debt of $40.58M: net cash of $371.01M. It had more liquid cash than debt at all 6 year-ends shown. Total debt was highest at the end of fiscal 2025 ($40.58M) and lowest at the end of fiscal 2020 ($0).
Year by year
| Fiscal year | Liquid cash | Total debt* | Net cash* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $411.59M* | $40.58M | $371.01M |
| 2024ended Dec 31, 2024 | $273.74M* | $21.85M | $251.89M |
| 2023ended Dec 31, 2023 | $99.7M | $14.13M | $85.58M |
| 2022ended Dec 31, 2022 | $142.14M | $0 | $142.14M |
| 2021ended Dec 31, 2021 | $133.54M | $0 | $133.54M |
| 2020ended Dec 31, 2020 | $80.09M | $0 | $80.09M |
Fiscal years as Definium Therapeutics, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Definium Therapeutics, Inc.
- The profitability of Definium Therapeutics, Inc.
- All of Definium Therapeutics, Inc.'s financials, charted
Companies of a similar size
- VSHVishay Intertechnology, Inc.
- SPHRSPHERE ENTERTAINMENT CO.
- OIIOCEANEERING INTERNATIONAL INC
- FINVFinVolution Group
- LAZLAZARD, INC.
Not investment advice. This page shows what Definium Therapeutics, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.